



Astec LifeSciences Ltd.

Date: April 8, 2022

To,
BSE Limited
P. J. Towers, Dalal Street,
Fort, Mumbai – 400 001

To,
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex,
Bandra (East), Mumbai-400 051

Ref.: BSE Scrip Code No. "533138"

Ref.: NSE Symbol "ASTEC"

Dear Sir / Madam,

Sub.: Intimation under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Credit Rating by ICRA Limited for Rs.300 Crore Commercial Paper programme of Astec LifeSciences Limited

In continuation to our letter dated March 30, 2022 for intimating Credit Rating assigned/re-affirmed by ICRA Limited vide its letter dated March 29, 2022 and pursuant to Regulation 30(6) read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("the Regulations"), this is to inform you that ICRA Limited, vide its letter dated April 7, 2022, has re-affirmed "**ICRA A1+**" rating (pronounced 'ICRA A one plus') to the aggregate Commercial Paper programme of Rs. 300 Crore (Rupees Three Hundred Crore Only) of the Company.

Further, pursuant to Regulation 30(8) of the SEBI Regulations, this intimation will also made available on the Company's website at www.astecls.com.

Kindly take the above on your records.

Yours faithfully,

For Astec LifeSciences Limited

Tejashree Pradhan
Company Secretary & Compliance Officer
(FCS 7167)



Regd. Office :
"Godrej One", 3rd Floor,
Pirojshanagar, Eastern Express Highway,
Vikhroli (East), Mumbai-400079,
Maharashtra, India
Telephone No. : 022- 25188010
Fax No.: 022-22618289
Email id: astecinfo@godrejastec.com
Website: www.astecls.com
CIN : L99999MH1994PLC076236